

Attorney Docket No.: ISPH-0569
Inventors: Anderson et al.
Serial No.: 09/853,409
Filing Date: May 11, 2001
Page 2

Listing of the Claims:

Claims 1-22 (canceled).

Claim 23 (previously presented): A composition comprising an oligonucleotide 5 to 50 nucleotides in length which is complementary to at least a portion of a Hepatitis C virus genomic or messenger mRNA which comprises SEQ ID NO: 6, and wherein said composition is in a form suitable for subcutaneous administration.

Claim 24 (previously presented): A method for inhibiting Hepatitis C virus gene expression in an animal comprising subcutaneously administering to said animal the composition of claim 23.

Claim 25 (previously presented): A method of inhibiting Hepatitis C virus replication in an animal comprising subcutaneously administering to said animal the composition of claim 23.

Claim 26 (previously presented) A method of treating a hepatitis C virus-associated disease in an animal comprising subcutaneously administering to said animal the composition of claim 23.

Claim 27 (canceled).

Attorney Docket No.: ISPH-0569
Inventors: Anderson et al.
Serial No.: 09/853,409
Filing Date: May 11, 2001
Page 3

Claim 28 (currently amended): A composition comprising an oligonucleotide consisting of SEQ ID NO: 6 and a diluent suitable for subcutaneous administration, ~~and wherein said composition is in a form suitable for subcutaneous administration.~~

Claim 29 (previously presented): A method for inhibiting Hepatitis C virus gene expression in an animal comprising subcutaneously administering to said animal the composition of claim 28.

Claim 30 (previously presented): A method of inhibiting Hepatitis C virus replication in an animal comprising subcutaneously administering to said animal the composition of claim 28

Claim 31 (previously presented): A method of treating a hepatitis C virus-associated disease in an animal comprising subcutaneously administering to said animal the composition of claim 28.